Pfizer Inc. $PFE Stock Position Raised by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio increased its stake in Pfizer Inc. (NYSE:PFE) by 2.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,408,993 shares of the biopharmaceutical company’s stock after acquiring an additional 57,703 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Pfizer were worth $67,645,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. Compound Planning Inc. lifted its holdings in shares of Pfizer by 17.3% during the first quarter. Compound Planning Inc. now owns 82,751 shares of the biopharmaceutical company’s stock valued at $2,324,000 after purchasing an additional 12,196 shares during the last quarter. Klingman & Associates LLC increased its stake in Pfizer by 1.5% in the 1st quarter. Klingman & Associates LLC now owns 28,450 shares of the biopharmaceutical company’s stock worth $799,000 after purchasing an additional 414 shares in the last quarter. Modern Wealth Management LLC increased its stake in Pfizer by 38.8% in the 1st quarter. Modern Wealth Management LLC now owns 63,184 shares of the biopharmaceutical company’s stock worth $1,804,000 after purchasing an additional 17,665 shares in the last quarter. Keebeck Wealth Management raised its holdings in Pfizer by 49.6% during the 1st quarter. Keebeck Wealth Management now owns 13,408 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 4,445 shares during the period. Finally, Volterra Technologies LP purchased a new stake in Pfizer during the first quarter valued at about $463,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $25.02 on Friday. The company has a market capitalization of $142.62 billion, a price-to-earnings ratio of 19.10 and a beta of 0.35. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The business’s 50-day moving average is $25.13 and its 200-day moving average is $26.18.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the firm earned $0.92 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is presently 131.30%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PFE shares. Guggenheim dropped their target price on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. BMO Capital Markets reduced their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research note on Tuesday, June 9th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA accepted Pfizer’s supplemental application for Talzenna plus Xtandi under Priority Review, a sign regulators are giving the prostate cancer expansion a faster path forward. Reuters article
• Positive Sentiment: Options activity was unusually heavy, with traders buying far more call options than normal, suggesting some investors are positioning for further upside in PFE.
• Neutral Sentiment: Articles discussing Pfizer’s roughly 7% dividend yield may help support the stock by reinforcing its income appeal, but they do not change the underlying business outlook. Motley Fool article
• Neutral Sentiment: Broader commentary on Pfizer’s oncology valuation suggests investors are still debating whether the company’s pipeline can justify a higher multiple. Kalkine Media article
• Negative Sentiment: Ongoing expanded patent litigation tied to mRNA vaccine technology remains a legal overhang and could create additional costs or uncertainty for Pfizer’s legacy COVID-19 franchise. Yahoo Finance article
• Negative Sentiment: Separately, policy risk remains a concern after reports that the Trump administration is considering steep tariffs on generic drugs, which could increase pressure across the pharmaceutical sector. Bloomberg article

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.